<p>2025 年 12 月 01 日- 下午 10:37</p>
<p>圣地亚哥，2025 年 12 月 01 日（GLOBE NEWSWIRE）-- <strong>Belite Bio, Inc</strong>（纳斯达克：BLTE）（“Belite Bio” 或 “公司”）是一家临床阶段的药物开发公司，专注于推进针对具有重大未满足医疗需求的退行性视网膜疾病的新型治疗方法。今天，公司宣布已定价进行一项承销的公开发行，发行 2,272,727 份美国存托股票（“ADSs”），每份代表其一普通股，公开发行价格为每份 ADS 154.00 美元。公司还授予承销商一个 30 天的选择权，以公开发行价格购买最多 340,909 份额外的 ADSs，扣除承销折扣和佣金。预计此次发行的总收益约为 3.5 亿美元，未扣除 Belite Bio 应支付的承销折扣、佣金和发行费用。此次发行的所有证券均由 Belite Bio 出售。预计发行的交割将在 2025 年 12 月 3 日左右进行，具体取决于满足惯常的交割条件。</p>
<p>Belite Bio 计划将此次发行的净收益用于（i）商业化准备，包括建立内部商业化团队、建立销售网络和系统，以及为未来产品的商业生产做准备（如获得批准），（ii）管道的开发和扩展，以及（iii）营运资金和其他一般企业用途。</p>
<p>摩根士丹利 \u0026 Co. LLC、Leerink Partners、BofA Securities 和 Cantor 担任此次发行的联合主承销商。H.C. Wainwright \u0026 Co.担任此次发行的主承销商。Maxim Group LLC 和 Titan Partners Group（美国资本伙伴的一个部门）担任此次发行的共同承销商。</p>
<p>此次发行是根据 Belite 的补充招股说明书和随附的招股说明书进行的，这些文件包含在 Belite 的 F-3ASR 表格注册声明中（文件编号：333-284521），该注册声明于 2025 年 1 月 27 日自动生效。初步补充招股说明书和随附的招股说明书的副本可以通过访问美国证券交易委员会（“SEC”）网站的 EDGAR 获取，网址为 www.sec.gov。最终的补充招股说明书将提交给 SEC，并将成为注册声明的一部分。最终补充招股说明书可在发布时从摩根士丹利 \u0026 Co. LLC 获取，注意：招股说明书部门，180 Varick Street，2 楼，纽约，纽约 10014，或通过电子邮件联系 prospectus@morganstanley.com；从 Leerink Partners LLC 获取，联合部门，53 State Street，40 楼，波士顿，马萨诸塞州 02109，电话（800）808-7525 分机 6105，或通过电子邮件联系 syndicate@leerink.com；从 BofA Securities 获取，注意：招股说明书部门，NC1-022-02-25，201 North Tryon Street，夏洛特，北卡罗来纳州 28255-0001，或通过电子邮件联系 dg.prospectus_requests@bofa.com；或从 Cantor Fitzgerald \u0026 Co.获取，注意：股本资本市场，110 E. 59th Street，6 楼，纽约，纽约 10022，或通过电子邮件联系 prospectus@cantor.com。</p>
<p>与这些证券相关的注册声明已向 SEC 提交并已自动生效。本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未注册或资格不符，则该等要约、征求或销售将是非法的。</p>
<p><strong>关于 Belite Bio</strong></p>
<p>Belite Bio 是一家临床阶段的药物开发公司，专注于推进针对具有重大未满足医疗需求的退行性视网膜疾病的新型治疗方法，如斯塔加特病 1 型（STGD1）和干性年龄相关性黄斑变性（AMD）晚期的地理性萎缩（GA），以及特定的代谢疾病。Belite 的主要候选药物 Tinlarebant 是一种口服治疗，旨在减少眼内双视网膜毒素的积累，已在青少年 STGD1 患者中完成了 3 期试验（DRAGON），并正在青少年 STGD1 患者中进行 2/3 期试验（DRAGON II）和在 GA 患者中进行 3 期试验（PHOENIX）。</p>
<p><strong>关于前瞻性声明的重要警示</strong></p>
<p>本新闻稿包含前瞻性声明，包括关于发行完成及预期收益用途、未来预期、计划和前景的声明，关于临床数据对患者潜在影响的声明，以及 Belite Bio 在其产品候选者的预临床活动、临床开发、监管里程碑和商业化方面的进展，Tinlarebant 治疗 STGD1 和 GA 的能力，完成相关临床试验和/或获得此类临床试验的中期/最终数据的时间；向监管机构提交试验数据以获得药物批准的时间，以及任何关于非历史事实的事项的声明，以及包含 “预期”、“将”、“相信”、“目标” 和其他类似表达的任何其他声明。无法保证发行将按照所述条款完成。发行的完成及其条款受多种因素的影响，其中许多因素超出了 Belite Bio 的控制，包括但不限于市场条件、习惯性交割条件的失败以及在注册声明中包含的招股说明书补充和随附招股说明书中列出的风险因素和其他事项。实际结果可能因与 Belite Bio 业务相关的各种重要因素而与前瞻性声明中所指示的结果有重大差异，包括但不限于 Belite Bio 证明其药物候选者的安全性和有效性的能力；其药物候选者的临床结果可能不支持进一步开发或监管批准；关于其临床试验的启动、招募和完成的时间预期，以及与之相关的数据；相关监管机构对 Belite Bio 药物候选者的监管批准的决定内容和时间；Tinlarebant 的潜在有效性，以及在 Belite Bio 向美国证券交易委员会提交的文件中更全面讨论的那些风险。所有前瞻性声明均基于目前可用的信息，Belite Bio 没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
<p><strong>媒体和投资者关系联系人：</strong></p>
<p><strong>Jennifer Wu /</strong> ir@belitebio.com</p>
<p><strong>Julie Fallon</strong> / belite@argotpartners.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5UQTFNQ00zTXpBd09UTTVJekl5TXpNM016ST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5UQTFNQ00zTXpBd09UTTVJekl5TXpNM016ST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OWQ0MTZmNGUtMTc4YS00ZjE0LWIxMzYtOTc1Y2EzZTgyMDQ1LTEyNDUyODUtMjAyNS0xMi0wMi1lbg==/tiny/Belite-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OWQ0MTZmNGUtMTc4YS00ZjE0LWIxMzYtOTc1Y2EzZTgyMDQ1LTEyNDUyODUtMjAyNS0xMi0wMi1lbg==/tiny/Belite-Bio-Inc.png"/></p>

BLTE

<p>Belite Bio 是一家临床阶段的药物开发公司，宣布以每股 154 美元的价格进行 3.5 亿美元的承销公开发行美国存托股票（ADSs）。此次发行包括承销商在 30 天内购买额外 ADSs 的选择权。募集资金将用于商业化、管道开发和一般企业用途。此次发行预计将于 2025 年 12 月 3 日完成，需满足惯常条件。摩根士丹利、Leerink Partners、BofA Securities 和 Cantor 正在管理此次发行</p>

<p>12/01/2025 - 10:37 PM</p>
<div class="lb-trans"><p>2025 年 12 月 01 日- 下午 10:37</p>
</div><p>SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- <strong>Belite Bio, Inc</strong> (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the Company at the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering to the Company are expected to be approximately $350.0 million before deducting underwriting discounts and commissions and offering expenses payable by Belite Bio. All of the securities in the offering are to be sold by Belite Bio. The closing of the offering is expected to occur on or about December 3, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>圣地亚哥，2025 年 12 月 01 日（GLOBE NEWSWIRE）-- <strong>Belite Bio, Inc</strong>（纳斯达克：BLTE）（“Belite Bio” 或 “公司”）是一家临床阶段的药物开发公司，专注于推进针对具有重大未满足医疗需求的退行性视网膜疾病的新型治疗方法。今天，公司宣布已定价进行一项承销的公开发行，发行 2,272,727 份美国存托股票（“ADSs”），每份代表其一普通股，公开发行价格为每份 ADS 154.00 美元。公司还授予承销商一个 30 天的选择权，以公开发行价格购买最多 340,909 份额外的 ADSs，扣除承销折扣和佣金。预计此次发行的总收益约为 3.5 亿美元，未扣除 Belite Bio 应支付的承销折扣、佣金和发行费用。此次发行的所有证券均由 Belite Bio 出售。预计发行的交割将在 2025 年 12 月 3 日左右进行，具体取决于满足惯常的交割条件。</p>
</div><p>Belite Bio intends to use the net proceeds of the offering for (i) commercialization preparation, including building our in-house commercialization team, establishing sales network and systems, and preparing for the commercial manufacture of our future products, if approved, (ii) development and expansion of pipelines, and (iii) working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>Belite Bio 计划将此次发行的净收益用于（i）商业化准备，包括建立内部商业化团队、建立销售网络和系统，以及为未来产品的商业生产做准备（如获得批准），（ii）管道的开发和扩展，以及（iii）营运资金和其他一般企业用途。</p>
</div><p>Morgan Stanley &amp; Co. LLC, Leerink Partners, BofA Securities and Cantor are acting as joint active book-running managers for the offering. H.C. Wainwright &amp; Co. is acting as lead manager for the offering. Maxim Group LLC and Titan Partners Group, a division of American Capital Partners, are acting as co-managers for the offering.</p>
<div class="lb-trans"><p>摩根士丹利 \u0026 Co. LLC、Leerink Partners、BofA Securities 和 Cantor 担任此次发行的联合主承销商。H.C. Wainwright \u0026 Co.担任此次发行的主承销商。Maxim Group LLC 和 Titan Partners Group（美国资本伙伴的一个部门）担任此次发行的共同承销商。</p>
</div><p>The offering is being made pursuant to a prospectus supplement and accompanying prospectus included in Belite’s registration statement on Form F-3ASR (File No. 333-284521), which became effective automatically on January 27, 2025. Copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting EDGAR on the U.S. Securities and Exchange Commission (“SEC”) website at www.sec.gov. A final prospectus supplement will be filed with the SEC and will form a part of the registration statement. When available, copies of the final prospectus supplement may be obtained from Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, or by email at dg.prospectus_requests@bofa.com; or Cantor Fitzgerald &amp; Co., Attention: Equity Capital Markets, 110 E. 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.</p>
<div class="lb-trans"><p>此次发行是根据 Belite 的补充招股说明书和随附的招股说明书进行的，这些文件包含在 Belite 的 F-3ASR 表格注册声明中（文件编号：333-284521），该注册声明于 2025 年 1 月 27 日自动生效。初步补充招股说明书和随附的招股说明书的副本可以通过访问美国证券交易委员会（“SEC”）网站的 EDGAR 获取，网址为 www.sec.gov。最终的补充招股说明书将提交给 SEC，并将成为注册声明的一部分。最终补充招股说明书可在发布时从摩根士丹利 \u0026 Co. LLC 获取，注意：招股说明书部门，180 Varick Street，2 楼，纽约，纽约 10014，或通过电子邮件联系 prospectus@morganstanley.com；从 Leerink Partners LLC 获取，联合部门，53 State Street，40 楼，波士顿，马萨诸塞州 02109，电话（800）808-7525 分机 6105，或通过电子邮件联系 syndicate@leerink.com；从 BofA Securities 获取，注意：招股说明书部门，NC1-022-02-25，201 North Tryon Street，夏洛特，北卡罗来纳州 28255-0001，或通过电子邮件联系 dg.prospectus_requests@bofa.com；或从 Cantor Fitzgerald \u0026 Co.获取，注意：股本资本市场，110 E. 59th Street，6 楼，纽约，纽约 10022，或通过电子邮件联系 prospectus@cantor.com。</p>
</div><p>A registration statement relating to these securities has been filed with the SEC and has become automatically effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>与这些证券相关的注册声明已向 SEC 提交并已自动生效。本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下未注册或资格不符，则该等要约、征求或销售将是非法的。</p>
</div><p><strong>About Belite Bio</strong></p>
<div class="lb-trans"><p><strong>关于 Belite Bio</strong></p>
</div><p>Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA.</p>
<div class="lb-trans"><p>Belite Bio 是一家临床阶段的药物开发公司，专注于推进针对具有重大未满足医疗需求的退行性视网膜疾病的新型治疗方法，如斯塔加特病 1 型（STGD1）和干性年龄相关性黄斑变性（AMD）晚期的地理性萎缩（GA），以及特定的代谢疾病。Belite 的主要候选药物 Tinlarebant 是一种口服治疗，旨在减少眼内双视网膜毒素的积累，已在青少年 STGD1 患者中完成了 3 期试验（DRAGON），并正在青少年 STGD1 患者中进行 2/3 期试验（DRAGON II）和在 GA 患者中进行 3 期试验（PHOENIX）。</p>
</div><p><strong>Important Cautions Regarding Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的重要警示</strong></p>
</div><p><em>This press release contains forward-looking statements, including statements about the completion of the offering and the expected use of proceeds, future expectations, plans and prospects, statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, the ability of Tinlarebant to treat STGD1 and GA, the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval, as well as any statements regarding matters that are not historical facts, and any other statements containing the words “expect”, “will”, “believe”, “target”, and other similar expressions. No assurance can be given that the offering will be completed on the terms described. Completion of the offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Belite Bio, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement. Actual results may also differ materially from those indicated in the forward-looking statements as a result of various important factors related to Belite Bio’s business, including but not limited to Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; expectations for the timing of initiation, enrollment and completion of, and data relating to, its clinical trials; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio’s drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.</em></p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括关于发行完成及预期收益用途、未来预期、计划和前景的声明，关于临床数据对患者潜在影响的声明，以及 Belite Bio 在其产品候选者的预临床活动、临床开发、监管里程碑和商业化方面的进展，Tinlarebant 治疗 STGD1 和 GA 的能力，完成相关临床试验和/或获得此类临床试验的中期/最终数据的时间；向监管机构提交试验数据以获得药物批准的时间，以及任何关于非历史事实的事项的声明，以及包含 “预期”、“将”、“相信”、“目标” 和其他类似表达的任何其他声明。无法保证发行将按照所述条款完成。发行的完成及其条款受多种因素的影响，其中许多因素超出了 Belite Bio 的控制，包括但不限于市场条件、习惯性交割条件的失败以及在注册声明中包含的招股说明书补充和随附招股说明书中列出的风险因素和其他事项。实际结果可能因与 Belite Bio 业务相关的各种重要因素而与前瞻性声明中所指示的结果有重大差异，包括但不限于 Belite Bio 证明其药物候选者的安全性和有效性的能力；其药物候选者的临床结果可能不支持进一步开发或监管批准；关于其临床试验的启动、招募和完成的时间预期，以及与之相关的数据；相关监管机构对 Belite Bio 药物候选者的监管批准的决定内容和时间；Tinlarebant 的潜在有效性，以及在 Belite Bio 向美国证券交易委员会提交的文件中更全面讨论的那些风险。所有前瞻性声明均基于目前可用的信息，Belite Bio 没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
</div><p><strong>Media and Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体和投资者关系联系人：</strong></p>
</div><p><strong>Jennifer Wu /</strong> ir@belitebio.com</p>
<div class="lb-trans"><p><strong>Jennifer Wu /</strong> ir@belitebio.com</p>
</div><p><strong>Julie Fallon</strong> / belite@argotpartners.com</p>
<div class="lb-trans"><p><strong>Julie Fallon</strong> / belite@argotpartners.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU5UQTFNQ00zTXpBd09UTTVJekl5TXpNM016ST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NTA1MCM3MzAwOTM5IzIyMzM3MzI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OWQ0MTZmNGUtMTc4YS00ZjE0LWIxMzYtOTc1Y2EzZTgyMDQ1LTEyNDUyODUtMjAyNS0xMi0wMi1lbg==/tiny/Belite-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/OWQ0MTZmNGUtMTc4YS00ZjE0LWIxMzYtOTc1Y2EzZTgyMDQ1LTEyNDUyODUtMjAyNS0xMi0wMi1lbg==/tiny/Belite-Bio-Inc.png"/></p>

Belite Bio 宣布 3.5 亿美元美国存托股票承销公开发行的定价 | BLTE 股票新闻